On Monday, UBS adjusted its outlook on Purple Innovation (NASDAQ:PRPL), a company specializing in the design and manufacture of mattresses and other comfort products. The firm's analyst has reduced the price target for Purple Innovation to $1.00, a decrease from the previous target of $2.00, while maintaining a Neutral rating on the stock.
The decision to revise the price target downward was attributed to a change in the target multiple to approximately 7 times from the prior 13 times. This adjustment is based on a reassessment of the company's expected performance and market conditions. Since Purple Innovation's initial public offering, the company has generally traded at a mid-teens enterprise value to EBITDA (EV/EBITDA) multiple. The former 13 times multiple was set in accordance with this historical trend.
The analyst notes that the mattress industry demand appears to be stabilizing, but cautions that unit growth could remain limited for an extended period. Additionally, due to Purple Innovation's predominantly fixed cost structure, the company might face challenges in reaching profitability if the sales growth does not meet expectations.
The firm's analyst maintains the full year 2025 EBITDA estimate for Purple Innovation at $16 million. The revised target multiple now sits at one full standard deviation below the company's historical average. This new valuation reflects concerns over the potential for sustained lower top-line growth and the implications of Purple Innovation's cost model on its profitability.
In other recent news, Purple Innovation has adopted a stockholder rights plan to safeguard its net operating losses (NOLs) valued at approximately $238 million. The company also experienced a 12.5% increase in sales year-over-year for the first quarter of 2024, but the adjusted net loss widened to $20.4 million from $14 million in the previous year. The company projects its 2024 net revenue to be between $540 million and $560 million, with adjusted EBITDA ranging from negative $20 million to negative $10 million.
At the annual stockholders meeting, all proposals were approved, including the re-election of eight directors and the ratification of BDO USA, LLP as the independent registered public accounting firm for 2024. Roth/MKM reiterated its Buy rating on Purple Innovation's stock, indicating confidence in the company's ongoing turnaround efforts.
InvestingPro Insights
As UBS revises its price target for Purple Innovation, real-time data and expert analysis become crucial for investors. According to InvestingPro data, Purple Innovation's market capitalization stands at $115.55M, with a negative P/E ratio of -0.78 as of Q1 2024, indicating that the company is not currently profitable. Despite a quarterly revenue growth of 12.47%, the company's revenue has declined by -2.4% over the last twelve months as of Q1 2024.
InvestingPro Tips highlight that Purple Innovation operates with a significant debt burden and may have trouble making interest payments on its debt, which is a critical concern for potential investors. Furthermore, analysts have recently revised their earnings downwards for the upcoming period, suggesting caution. On a more positive note, the company's liquid assets exceed its short-term obligations, providing some financial flexibility. For those interested in a deeper dive, there are 11 additional InvestingPro Tips available for Purple Innovation, which can be explored at https://www.investing.com/pro/PRPL. To access these insights, use coupon code PRONEWS24 for up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.